25.02.2019

08:45 - 09:30  Opening and welcome + Honorary award Keynote lecture
Moderation: J. Tabernero\textsuperscript{1}, A.A. Adjei\textsuperscript{2}, ¹Medical Oncology, Vall d’Hebron University Hospital. Vall d’Hebron Institute of Oncology VHIO., Barcelona, ES, ²Oncology, Mayo Clinic, Rochester, US

08:45 - 08:45  Session DOI

08:45 - 08:50  Welcome address - ESMO
J. Tabernero, Vall d’Hebron University Hospital. Vall d’Hebron Institute of Oncology VHIO., Barcelona, ES

08:50 - 08:55  Welcome address - TAT 2019 Scientific Committee
A.A. Adjei, Mayo Clinic, Rochester, US

08:55 - 09:00  Presentation of the TAT 2019 Honorary Award
A.A. Adjei, Mayo Clinic, Rochester, US

09:00 - 09:30  Development of Cyclin-Dependent Kinase Inhibitors: A Brief History and Future Directions
G. Shapiro, Dana Farber Cancer Institute, Boston, US
09:35 - 11:00  **Liquid biopsies as biomarkers for early drug development**  
Amphithéâtre Bordeaux

Moderation: L. Ellis¹, C. Massard², ¹Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, US, ²Ditep, Gustave Roussy - Cancer Campus, Villejuif, FR

09:35 - 09:35  **Session DOI**

09:35 - 09:45  **Introduction**  
C. Massard, Gustave Roussy - Cancer Campus, Villejuif, FR

09:45 - 10:00  **Technical insights on liquid biopsies: Available techniques, sensitivity, GMP**  
P. Laurent-Puig, Paris Descartes University, Paris, FR

10:00 - 10:15  **Driving the pharmacological audit trail through liquid biopsies**  
J. De Bono, The Institute of Cancer Research (ICR), London, GB

10:15 - 10:30  **Single circulating tumour cell genomics as a biomarker for early drug development**  
N. Stoecklein, Heinrich-Heine-University Düsseldorf, Düsseldorf, DE

10:30 - 10:45  **Tumour mutational burden during treatment: Implications for immuno-oncology**  
N. Rizvi, Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US

10:45 - 11:00  **Q&A and conclusion**  
L. Ellis, The University of Texas MD Anderson Cancer Center, Houston, US
11:30 - 13:00  Emerging therapeutic strategies  Amphithéâtre Bordeaux

Moderation: R. Plummer¹, T. Yap², D.S. Tan³, ¹The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle upon Tyne, GB, ²Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, US, ³Medical Oncology, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

11:30 - 11:30  Session DOI

11:30 - 11:35  Introduction
R. Plummer, Northern Institute for Cancer Research University of Newcastle, Newcastle upon Tyne, GB

11:35 - 11:50  DNA polymerase Theta (POLθ) as an anticancer target
G. Higgins, University of Oxford, Oxford, GB

11:50 - 12:05  Targeting the WNT pathway for cancer therapy
D.S. Tan, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

12:05 - 12:20  HIF-2a
E. Jonasch, The University of Texas MD Anderson Cancer Center, Houston, US

12:20 - 12:35  Cancer evolution as a therapeutic target
A. Bardelli, University Of Torino - Candiolo Cancer Institute - FPO - IRCCS, Candiolo, IT

12:35 - 12:50  Clinical development of oxidative phosphorylation (OXPHOS) inhibitors
T. Yap, The University of Texas MD Anderson Cancer Center, Houston, US

12:50 - 12:55  Q&A
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 14:00</td>
<td>Meet the Professor - TRK fusion cancer: A tumour-agnostic treatment target</td>
<td>342</td>
</tr>
<tr>
<td></td>
<td>Moderation: U. Lassen(^1), C. Marchiò(^2), (^1)Dept. Of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, (^2)Department Of Medical Sciences, Università degli Studi di Torino, Torino, IT</td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:00</td>
<td>Session DOI</td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:20</td>
<td>TRK fusion cancer: epidemiology, treatment and clinical cases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>U. Lassen, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK</td>
<td></td>
</tr>
<tr>
<td>13:20 - 13:40</td>
<td>NTRK gene fusions: mechanisms and testing</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Marchiò, Università degli Studi di Torino, Torino, IT</td>
<td></td>
</tr>
<tr>
<td>13:15 - 14:00</td>
<td>Workshop: How to peer review a manuscript</td>
<td>341</td>
</tr>
<tr>
<td></td>
<td>Moderation: L. Ellis(^1), A.A. Adjei(^2), (^1)Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, US, (^2)Oncology, Mayo Clinic, Rochester, US</td>
<td></td>
</tr>
<tr>
<td>13:15 - 13:15</td>
<td>Session DOI</td>
<td></td>
</tr>
<tr>
<td>13:15 - 13:20</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. Ellis, The University of Texas MD Anderson Cancer Center, Houston, US</td>
<td></td>
</tr>
<tr>
<td>13:20 - 13:30</td>
<td>What YOU should include in your manuscripts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. Ellis, The University of Texas MD Anderson Cancer Center, Houston, US</td>
<td></td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td>What editors (and authors) look for in good peer review</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A.A. Adjei, Mayo Clinic, Rochester, US</td>
<td></td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td>Conclusion and take-away message</td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. Ellis, The University of Texas MD Anderson Cancer Center, Houston, US</td>
<td></td>
</tr>
</tbody>
</table>
14:05 - 14:05 Session DOI

14:05 - 14:20 3O - Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials

A. Varga¹, A. Bernard-Tessier¹, E. Auclin², L. Mezquita Pérez¹, C. Baldini¹, D. Planchard³, A. Marabelle⁴, A. Hollebecque¹, B. Besse⁴, C. Massard⁴, J. De Bono¹, C. Massard², The Institute of Cancer Research (ICR), London, GB, Ditep, Gustave Roussy - Cancer Campus, Villejuif, FR

14:20 - 14:30 Q&A

J. De Bono¹, C. Massard², The Institute of Cancer Research and Royal Marsden, London, GB, Gustave Roussy - Cancer Campus, Villejuif, FR

14:30 - 14:45 2O - A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors

A. Tolcher¹, D. Fang², Y. Li³, Y. Tang⁴, J. Ji², H. Wang², R. Karim¹, C. Rosas¹, Y. Huang², Y. Zhai², J. De Bono¹, C. Massard², The Institute of Cancer Research and Royal Marsden, London, GB, Gustave Roussy - Cancer Campus, Villejuif, FR

14:45 - 14:55 Q&A

J. De Bono¹, C. Massard², The Institute of Cancer Research (ICR), London, GB, Gustave Roussy - Cancer Campus, Villejuif, FR

14:55 - 15:10 29O - The 18-year-old clinical trial inclusion limit is a major barrier in the access to immunotherapies and targeted therapies for adolescents and young adults (AYAs) with cancer

T. De Rojas¹, A. Neven¹, M. Garcia-Abos², L. Moreno³, N. Gaspar⁴, J. Peron¹, J. De Bono¹, C. Massard², EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE, Hospital Donostia, San Sebastian, ES, Hospital Niño Jesús, Madrid, ES, Gustave Roussy Cancer Campus, Villejuif, FR

15:10 - 15:20 Q&A

J. De Bono¹, C. Massard², The Institute of Cancer Research and Royal Marsden, London, GB, Gustave Roussy - Cancer Campus, Villejuif, FR
15:45 - 15:45  **Session DOI**

15:45 - 15:50  **Introduction**
V. Ribrag, Institut Gustave Roussy, Villejuif, FR

15:50 - 16:10  **Epigenetic dysregulation in hematological malignancies**
O. Bernard, Gustave Roussy - Cancer Campus, Villejuif, FR

16:10 - 16:30  **PRMT5 in hematological malignancies**
A. Dhar, GlaxoSmithKline USA, Collegeville, US

16:30 - 16:50  **BiTEs for cancer therapy**
R.C. Bargou, University of Würzburg, Würzburg, DE

16:50 - 17:10  **Application of CRISPR screen to guide therapy for lymphoma**
H.G. Wendel, Memorial Sloan Kettering Cancer Center, New York, US

17:10 - 17:15  **Q&A**
26.02.2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td><strong>Session DOI</strong></td>
</tr>
<tr>
<td>08:00</td>
<td>Introduction</td>
</tr>
<tr>
<td></td>
<td>J. De Bono, The Institute of Cancer Research (ICR), London, GB</td>
</tr>
<tr>
<td>08:05</td>
<td><strong>What you must know about writing a research grant proposal</strong></td>
</tr>
<tr>
<td></td>
<td>J. De Bono, The Institute of Cancer Research (ICR), London, GB</td>
</tr>
<tr>
<td>08:30</td>
<td><strong>Writing your first Young Investigator grant</strong></td>
</tr>
<tr>
<td></td>
<td>J. Mateo, Vall d’Hebron University Hospital, Barcelona, ES</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>09:00 - 10:30</td>
<td>Immune checkpoint combinations: How to marry rationally</td>
</tr>
<tr>
<td></td>
<td>Moderation: G. Giaccone¹, M. Gutierrez², ¹Oncology, Lombardi Cancer Center Georgetown University, Washington DC, US, ²Medical Oncology, The John Theurer Cancer Center, Hackensack, US</td>
</tr>
<tr>
<td>09:00 - 09:00</td>
<td>Session DOI</td>
</tr>
<tr>
<td>09:00 - 09:05</td>
<td>Maximizing the potential of IO combinations: Successes and failures</td>
</tr>
<tr>
<td>09:05 - 09:25</td>
<td>The rationale behind immunotherapy combinations</td>
</tr>
<tr>
<td>09:25 - 09:45</td>
<td>Leveraging single-cell technologies for discovery of novel IO drug combinations</td>
</tr>
<tr>
<td>09:45 - 10:05</td>
<td>Preclinical models to assess timing of combination regimens</td>
</tr>
<tr>
<td>10:05 - 10:25</td>
<td>Immuno-oncology combination in patients with pre-existing molecular alteration (EGFR ALK BRAF and other)</td>
</tr>
<tr>
<td>10:25 - 10:30</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>
11:00 - 11:00  
**Session DOI**

11:00 - 11:15  
**8O - 89Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors**  
D. Giesen¹, L. Broer¹, M. Lub-De Hooge¹, I. Popova², B. Howng², O. Vasiljeva², E.G.E. De Vries¹, M. Pooi³, ¹University Medical Center Groningen, Groningen, NL, ²CytomX Therapeutics Inc., South San Francisco, US, ³Leiden University Medical Center, Leiden, NL

11:15 - 11:25  
**Q&A**  
G. Giaccone¹, A.A. Adjei², ¹Lombardi Cancer Center Georgetown University, Washington DC, US, ²Mayo Clinic, Rochester, US

11:25 - 11:40  
**7O - Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)**  

11:40 - 11:50  
**Q&A**  
G. Giaccone¹, A.A. Adjei², ¹Lombardi Cancer Center Georgetown University, Washington DC, US, ²Mayo Clinic, Rochester, US

11:50 - 12:05  
**25O - Use of CTTA to predict treatment response in patients with EGFR T790M+ NSCLC treated with osimertinib**  
W.L. Tan¹, T.A. Tran Nguyen², T.S. Koh², T. Priyanthi Hennedige², C. Yip², S.H. Tan², D. Tan¹, C.H. Thng², D. Lim¹, Q.S. Ng¹, ¹National Cancer Center Singapore, Singapore, Singapore, SG, ²National Cancer Centre, SINGAPORE, SG

12:05 - 12:15  
**Q&A**  
G. Giaccone¹, A.A. Adjei², ¹Lombardi Cancer Center Georgetown University, Washington DC, US, ²Mayo Clinic, Rochester, US
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 - 13:30</td>
<td><strong>Workshop: How to choose a drug to study, biomarkers, etc.</strong></td>
<td>Room 341</td>
</tr>
<tr>
<td></td>
<td>Moderation: G. Schwartz¹, S. Bates², ¹Columbia University Medical Center College of Physicians &amp; Surgeons - New York Presbyterian Hospital, New York, US, ²Medicine Hematology/medical Oncology, Columbia University, New York, US</td>
<td></td>
</tr>
</tbody>
</table>

12:45 - 12:45  **Session DOI**

12:45 - 12:55  **Drug development: Lessons from failure**
S. Bates, Columbia University, New York, US

12:55 - 13:05  **Drug development: Lessons from success**
G. Schwartz, Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US

13:05 - 13:25  **Round table discussion**
S. Bates¹, G. Schwartz², ¹Columbia University, New York, US, ²Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US

13:25 - 13:30  **Conclusion and take-away message**
S. Bates¹, G. Schwartz², ¹Columbia University, New York, US, ²Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US
13:35 - 15:05  Immune checkpoint inhibitors with targeted agents: Challenging marriages
Amphithéâtre Bordeaux
Moderation: I. Melero¹, G. Curigliano². ¹Laboratory Of Immunology, Clinica Universitaria de Navarra, Pamplona, ES, ²Early Drug Development for Innovative Therapies Division, University Of Milano, Istituto Europeo di Oncologia, Milan, IT

13:35 - 13:35  Session DOI

13:35 - 13:40  Introduction: Making challenging marriages work
T. Yap, MD Anderson Cancer Center, Houston, US

13:40 - 14:00  PARP and PD-1/PDL1 inhibition
G. Curigliano, Istituto Europeo di Oncologia, Milan, IT

14:00 - 14:20  PI3K/AKT + PD-1/PD-L1 inhibition
S. Ansell, Mayo Clinic, Rochester, US

14:20 - 14:40  MEK + PD-1/PD-L1 inhibition
C. Massard, Gustave Roussy - Cancer Campus, Villejuif, FR

14:40 - 15:00  Epigenetics and Immunotherapy
I. Melero, Clinica Universitaria de Navarra, Pamplona, ES

15:00 - 15:05  Q&A
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30</td>
<td><strong>Methodological issues in IO</strong></td>
<td>Moderation: J. Tabernero(^1), A.A. Adjei(^2), 1Medical Oncology, Vall d’Hebron University Hospital. Vall d’Hebron Institute of Oncology VHIO., Barcelona, ES, 2Oncology, Mayo Clinic, Rochester, US</td>
</tr>
<tr>
<td>15:30 - 15:30</td>
<td><strong>Session DOI</strong></td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:35</td>
<td><strong>Introduction</strong></td>
<td></td>
</tr>
<tr>
<td>15:35 - 15:55</td>
<td><strong>Biomarkers &amp; endpoints</strong></td>
<td>A. Marabelle, Gustave Roussy, Villejuif, FR</td>
</tr>
<tr>
<td>15:55 - 16:15</td>
<td><strong>Imaging biomarkers</strong></td>
<td>E.G.E. De Vries, University Medical Center Groningen, Groningen, NL</td>
</tr>
<tr>
<td>16:15 - 16:35</td>
<td><strong>Scheduling, dose optimisation</strong></td>
<td>E. Calvo, Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES</td>
</tr>
<tr>
<td>16:35 - 16:55</td>
<td><strong>Complex innovative designs</strong></td>
<td>Y. Shyr, Vanderbilt University School of Medicine, Nashville, US</td>
</tr>
<tr>
<td>16:55 - 17:15</td>
<td><strong>Report from MDICT</strong></td>
<td>L. Seymour, Canadian Cancer Trials Group, Kingston, CA</td>
</tr>
<tr>
<td>17:15 - 17:30</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Details</td>
</tr>
<tr>
<td>------</td>
<td>---------</td>
<td>---------</td>
</tr>
</tbody>
</table>
| 17:30 - 18:00 | Selected Poster Presentation | Amphithéâtre Bordeaux  
Moderation: J. De Bono\(^1\), E. Calvo\(^2\),  
\(^1\)The Institute of Cancer Research (ICR), London, GB,  
\(^2\)Dept. Early Clinical Drug Development, Hospital Madrid Norte San Chinarro - Centro  
Integral Oncologico Clara Campal, Madrid, ES |
| 17:30 - 17:30 | Session DOI |  |
| 17:30 - 17:35 | 4P - Novel applications of MVA to improve outcomes in immunooncology |  
C. Heery\(^1\), C. Pico-Navarro\(^2\), T. Adams\(^3\), L. Bauman\(^4\), J. Medina\(^3\), M. Hinterberger\(^5\), A. Heiseke\(^3\), H. Lauterbach\(^3\), H. Hochrein\(^3\), \(^1\)Bavarian Nordic, Morrisville, US,  
\(^2\)Bavarian Nordic, Cancer Immunotherapy Division, Madrid, ES,  
\(^3\)Bavarian Nordic GmbH, Martinsried (Planegg), DE,  
\(^4\)Bavarian Nordic, Inc., Roswell, US,  
\(^5\)Bavarian Nordic, Planegg, DE |
| 17:35 - 17:40 | Q&A |  
J. De Bono\(^1\), E. Calvo\(^2\),  
\(^1\)The Institute of Cancer Research (ICR), London, GB,  
\(^2\)Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES |
| 17:40 - 17:45 | 9P - Safety profile and therapeutic efficacy of one cycle of \(^{177}\text{Lu}\)prostate-specific membrane antigen (PSMA) in end stage metastatic castration-resistant prostate cancer patients with low performance status |  
M. Gupta\(^1\), P. Choudhury\(^2\), S. Rawal\(^1\), H. Goej\(^3\), V. Talwar\(^1\), K. Dutta\(^1\), A. Singh\(^1\), \(^1\)Rajiv Gandhi Cancer Institute & Research Centre, Delhi, IN,  
\(^2\)Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN,  
\(^3\)Amity University, Uttar Pradesh, IN |
| 17:45 - 17:50 | Q&A |  
J. De Bono\(^1\), E. Calvo\(^2\),  
\(^1\)The Institute of Cancer Research (ICR), London, GB,  
\(^2\)Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES |
| 17:50 - 17:55 | 30P - Dynamic change in the distribution of cancer types in oncology phase I trials |  
Cancer Center Hospital, Tokyo, JP |
| 17:55 - 18:00 | Q&A |  
J. De Bono\(^1\), E. Calvo\(^2\),  
\(^1\)The Institute of Cancer Research (ICR), London, GB,  
\(^2\)Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES |
| 18:00 - 18:45 | Cocktail and Poster viewing | Hall Bordeaux  
Moderation: J. De Bono\(^1\), E. Calvo\(^2\),  
\(^1\)The Institute of Cancer Research (ICR), London, GB,  
\(^2\)Dept. Early Clinical Drug Development, Hospital Madrid Norte San Chinarro - Centro  
Integral Oncologico Clara Campal, Madrid, ES |
| 18:00 - 18:05 | 1P - PIWI proteins play oncogenic functions in pancreatic cancer |  |
W. Li¹, J. Martinez Useros², M. Fernández-Aceñero³, N. García Carbonero², J. García Foncillas⁴, ¹University Hospital Fundacion Jimenez Diaz, Madrid, ES, ²University Hospital “Fundacion Jimenez Diaz”, Madrid, ES, ³Clinico San Carlos University Hospital, Madrid, ES, ⁴University Hospital “Fundacion Jimenez Diaz”, MADRID, ES

18:05 - 18:10  
⁴P - Novel applications of MVA to improve outcomes in immunooncology  

18:10 - 18:15  
⁵P - Establishment and application of a panel of PBMC-humanized mouse tumor models in cancer immunotherapy  
L. Bourre¹, L. Zhang¹, S. Qi¹, H. Wu¹, L. Zhao¹, X. An¹, W. Tan², X. Fu², M. Qiao¹, Q. Shi¹, W. Yang¹, ¹Crown Bioscience Inc., San Diego, US, ²Taicang Blood Center, Taicang, Suzhou, CN

18:15 - 18:20  
⁹P - Safety profile and therapeutic efficacy of one cycle of [177Lu]prostate-specific membrane antigen (PSMA) in end stage metastatic castration-resistant prostate cancer patients with low performance status  
M. Gupta¹, P. Choudhury², S. Rawal¹, H. Goel³, V. Talwar¹, K. Dutta¹, A. Singh¹, ¹Rajiv Gandhi Cancer Institute & Research Centre, Delhi, IN, ²Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN, ³Amity University, Uttar Pradesh, IN

18:20 - 18:25  
⁶P - Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors  
S. Amaral¹, M. Casal Moura², J. Carvalho¹, A. Chaves¹, E. Jesus¹, G. Sousa¹, ¹Portuguese Institute of Oncology, Coimbra, PT, ²University of Porto, Porto, PT

18:25 - 18:25  
¹⁰P - Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?  
L. Leroy¹, T. Satar¹, C. Baldini², P. Martin-Romano¹, A. Hollebecque², J.-M. Michot¹, V. Ribrag¹, C. Massard³, X. Paolletti¹, S. Postel Vinay¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy, Villejuif, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR

18:25 - 18:25  
¹¹P - Photosensitizer-based multimodal nanocomposites as a theranostic agent for near infrared (NIR)-guided cancer-targeting synergistic chemo-phototherapy  
T. Ponraj¹, R. Vivek², M. Paulpandi¹, K. Vimala³, A. Vasanthakumar¹, S. Kannan⁴, ¹Bharathiar University, Coimbatore, IN, ²Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, IN, ³Periyar University, Salem, IN, ⁴Periyar University, Salem, IN

18:25 - 18:25  
¹²P - Targeting HIF1α/AP1 in hypoxia by novel 7-amino-6-halogeno-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides  
A. Scherbakov¹, G. Buravchenko², L. Dezhengkova², A. Shchekotikhin², ¹IN. N. Blokhin Russian Cancer Research Center, Moscow, RU, ²Gause Institute of New Antibiotics,
18:25 - 18:25 13P - Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways

G. Umapathy1, J. Van Den Eynden2, D. Cervantes-Madrid3, J. Szyszki3, J. Guan3, R. Palmer3, B. Hallberg3, 1University of Gothenburg - The Sahlgrenska Academy, Goeteborg, SE, 2Gothenburg University, Gothenburg, SE, 3The Sahlgrenska Academy at Gothenburg University, Gothenburg, SE

18:25 - 18:25 14P - Butein inhibits solid tumors cell viability, colony, and tumor growth via STAT3 signaling pathway and enhance the anti-cancer effects of Frondoside-A and camptothecin

S. Attoub1, S. Sulaiman2, K. Arafat2, 1College of Medicine and Health Sciences / United Arab Emirates University, Al Ain, AE, 2College of Medicine & Health Sciences / United Arab Emirates University, Al Ain, AE

18:25 - 18:25 15P - ATM loss in NSCLC increases sensitivity to cisplatin and PARP inhibition

D.G. Bebb1, L. Petersen2, J. Moore2, A. Elegbede2, S. Lees-Miller2, 1Tom Baker Cancer Centre, Calgary, CA, 2University of Calgary, Calgary, CA

18:25 - 18:25 16P - Inhibition of PDE4 sensitizes drug resistant NSCLC to TKI therapy

S. Mukherjee, D. Suresh, A. Upendran, R. Kannan, University of Missouri, Columbia, US

18:25 - 18:25 17P - microRNA-16-5p enhances radiosensitivity through modulating cyclin D1/E1

L. Gan, F. Wang, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, CN

18:25 - 18:25 18P - Choline transporter-like protein 1 (CTL1/SLC44A1) is a therapeutic target molecule for prostate cancer therapy

M. Inazu, I. Saiki, H. Uchino, T. Yamanaka, Tokyo Medical University, Tokyo, JP

18:25 - 18:25 19P - Preclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC)

C.L. Lee1, S. Toomey2, A. Farrell3, B. Hennessy3, 1St Vincents University Hospital, Dublin, IE, 2Royal College of Surgeons in Ireland, Dublin, IE, 3Royal College of Surgeons in Ireland, Beaumont Hospital, DUBLIN, IE

18:25 - 18:25 20P - Nischarin expression in colon cancer

M. Cavic, M. Vidosavljevic, S. Radulovic, J. Grahovac, Institute for Oncology and Radiology of Serbia, Belgrade, RS

18:25 - 18:25 21P - Evaluation of magnetic nanoparticle of irinotecan for personalized treatment of colorectal cancer

A. Singh, Indian Institute of Science, Bangalore, IN
22P - Therapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer
H. Kim, S. Son, Hanyang University, Seoul, KR

18:25 - 18:25

23P - Matricellular protein CCN3/NOV regulates tumorigenesis in triple-negative breast cancer
S. Son, H. Kim, I. Shin, Hanyang University, Seoul, KR

18:25 - 18:25

24P - Reactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients
O. Trifanescu1, F. Topleceanu2, B.-A. Gusoiu1, L. Gales1, R. Anghel2, 1National Institute of Oncology A.Treistiaeanu, Bucharest, RO, 2Central Universitary Emergency Military Hospital, Bucharest, RO, 3UNIVERSITY OF MEDICINE AND PHARMACY "CAROL DAVILA", Bucharest, RO

18:25 - 18:25

26P - Texture analysis in contrast enhanced CT: New method to predict prognosis of small cell lung cancer treated with platinum-based chemotherapy
M. Wang, X. Ma, West China Hospital, Sichuan University, Chengdu, CN

18:25 - 18:25

27P - Detection of genomic alterations in breast cancer (BC) patients with paired plasma and tumour specimens

18:25 - 18:25

28P - Simultaneous unbiased and absolute quantification of a 500 protein panel in pancreatic cancer plasma using HRM mass spectrometry
H. Yu, J. Vowinckel, C. Escher, D. Heinzmann, N. Dupuis, Biognosys AG, Schlieren, CH

18:25 - 18:30

30P - Dynamic change in the distribution of cancer types in oncology phase I trials
J. Sato, K. Itahashi, T. Shimizu, T. Koyama, Y. Fujiwara, N. Yamamoto, National Cancer Center Hospital, Tokyo, JP

18:25 - 18:30

31P - Comprehensive genomic profiling of Chinese esophageal squamous cell carcinoma patients
Y. Li1, Y. Wu2, W. Fu3, L. Liu4, Z. Tian5, S. Wen6, K. Zhang6, M. Yao7, A. Liu7, Y. Zhou7, 1Zhejiang Cancer Hospital, Hangzhou, CN, 2Dongguan people's hospital, Dongguan, CN, 3Affiliated cancer hospital and institute of Guangzhou Medical University, Guangzhou, CN, 4Jiangsu province hospital, Nanjing, CN, 5Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, 6People's Hospital of Wuzhou, Wuzhou, CN, 7Origimed, Shanghai, CN

18:30 - 18:30

32P - Clinical correlation between different CKIT exon mutations and clinical outcome imatinib mesylate treatment in gastrointestinal stromal tumor (GIST) patients
G. Zakaria1, N. Allahlouhi2, A. Bahnsay3, O. Khorshid3, 1Cairo Oncology Center Cairo University-CairoCure, Cairo, EG, 2NCi, Cairo, EG, 3NCi, Cairo, EG
33P - Proteomic analysis of UKF-NB-4 cells reveals a stimulatory activity of MT-3 on cellular senescence and apoptosis

M.A. Merlos Rodrigo¹, H. Buchtelova², V. Strmiska², A. Jimenez Jimenez², I. Casal³, V. Adam², Z. Heger², ¹Medical Faculty, University of Brno, Prague, CZ, ²Mendel University of Brno, Brno, CZ, ³CIB-CSIC, Madrid, ES

34P - Impact of treatment with bilastine for PD-1/PD-L1 inhibitors induced rash

T. Hirata, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, JP

35P - Enhancement of high-LET radiation-induced lung cancer cell apoptosis by Antennapedia proteins (ANTP)-SmacN7

Y. Xie, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, CN

36P - Structural diversity of the cardenolide calotropin renders it as a targeted therapy for harnessing TNBC progression through tuning nitric oxide (NO) levels

R.A. Ellayeh¹, R. Youness¹, H. Askary², A. Abdelmotaal³, R. Assal¹, ¹German University in Cairo, Cairo, EG, ²Cairo University, Cairo, EG, ³King Khalid University, Abha, SA

37P - Genomics and pharmacogenomics analyses of cancer cell lines using the CellMinerCDB and CellMiner web-applications

W. Reinhold¹, Y. Pommier², ¹NCI/NIH, Bethesda, US, ²National Cancer Institute, Bethesda, US
27.02.2019

09:00 - 10:30  Monotherapy vulnerability- Cell cycle checkpoint and DNA damage/repair inhibitors

Amphithéâtre Bordeaux

Moderation: G. Schwartz¹, G. Shapiro², ¹Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ²Medical Oncology, Dana Farber Cancer Institute, Boston, US

09:00 - 09:00  Session DOI

09:00 - 09:05  Introduction

G. Shapiro, Dana-Farber Cancer Institute, Boston, US

09:05 - 09:25  DNA repair deficiency in ovarian cancer: Use of short-term patient-derived organoids to predict DNA repair inhibitor response

A. D'Andrea, Dana-Farber Cancer Institute, Boston, US

09:25 - 09:45  Monotherapy vulnerability to ATR inhibition: Tumors harboring ALT, ATM deficiency and other alterations

R. Plummer, Northern Institute for Cancer Research University of Newcastle, Newcastle upon Tyne, GB

09:45 - 10:05  Replication stress and DNA repair inhibitors

G. Shapiro, Dana Farber Cancer Institute, Boston, US

10:05 - 10:25  Trial designs and targeting DNA repair

J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES

10:25 - 10:30  Q&A
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-12:30</td>
<td>KRAS</td>
<td>Moderation: U. Banerji(^1), S. Bates(^2), 1Drug Development Unit, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, 2Medicine Hematology/medical Oncology, Columbia University, New York, US</td>
</tr>
<tr>
<td>11:00 - 11:00</td>
<td><strong>Session DOI</strong></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:05</td>
<td><strong>Introduction</strong></td>
<td>S. Bates, Columbia University, New York, US</td>
</tr>
<tr>
<td>11:05 - 11:25</td>
<td><strong>Allele specific KRAS G12C inhibitors: from mechanism to modulation of antitumor effect</strong></td>
<td>P. Lito, Memorial Sloan-Kettering Cancer Center, New York, US</td>
</tr>
<tr>
<td>11:25 - 11:45</td>
<td><strong>Update on the KRAS program at NCI</strong></td>
<td>D. Nissley, Frederick National Laboratory/Leidos, Frederick, US</td>
</tr>
<tr>
<td>11:45 - 12:05</td>
<td><strong>Phase I trial of RO5126766 a MEK-RAF inhibitor in solid tumours and myeloma driven by RAS driven cancers</strong></td>
<td>U. Banerji, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB</td>
</tr>
<tr>
<td>12:05 - 12:25</td>
<td><strong>Inhibiting K-ras in the clinic: The saga continues</strong></td>
<td>A.A. Adjei, Mayo Clinic, Rochester, US</td>
</tr>
<tr>
<td>12:25 - 12:30</td>
<td><strong>Q&amp;A</strong></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session/DOI</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>13:30 - 13:30</td>
<td>Session DOI</td>
<td>Amphithéâtre Bordeaux</td>
</tr>
<tr>
<td>13:55 - 14:15</td>
<td>Targeting RET</td>
<td>Amphithéâtre Bordeaux</td>
</tr>
<tr>
<td>14:15 - 14:35</td>
<td>TPRSSZ / FGFR</td>
<td>Amphithéâtre Bordeaux</td>
</tr>
<tr>
<td>14:35 - 14:55</td>
<td>ROS1 and ALK</td>
<td>Amphithéâtre Bordeaux</td>
</tr>
<tr>
<td>14:55 - 15:00</td>
<td>Q&amp;A</td>
<td>Amphithéâtre Bordeaux</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>Take home messages and close</td>
<td>Amphithéâtre Bordeaux</td>
</tr>
<tr>
<td>15:00 - 15:00</td>
<td>Session DOI</td>
<td>Amphithéâtre Bordeaux</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>Take home messages and close</td>
<td>Amphithéâtre Bordeaux</td>
</tr>
</tbody>
</table>